Ibrahim Alper Yavuz1, Ozdamar Fuad Oken2, Ahmet Ozgur Yildirim2, Fatih Inci2, Erman Ceyhan2, Utku Gurhan2. 1. Department of Orthopaedics and Traumatology, University of Health Science, Ankara Numune Training and Research Hospital, Ankara, Turkey. dribrahimyavuz@hotmail.com. 2. Department of Orthopaedics and Traumatology, University of Health Science, Ankara Numune Training and Research Hospital, Ankara, Turkey.
Abstract
PURPOSE: Vancomycin powder (VP) has been used to prevent periprosthetic joint infection (PJI). However, studies investigating the efficacy of VP to prevent infection in primary total knee arthroplasty (TKA) are very rare. The purpose of this study was to investigate the efficacy of VP application to prevent PJI in TKA. METHODS: Between 2012 and 2016, 976 consecutive patients who underwent primary TKA were included in the present study. Patients were divided into two groups. There were 474 patients (48.6%) in the VP group and 502 patients in the control group (51.4%). Except for VP, all procedures were the same in both groups. In the VP group, 2 g of VP was poured into the joint just before the fascia was closed. Average follow-up was 53.2 months (24-84 months). RESULTS: Infection was found in 4 (0.84%) of 474 patients in the VP group and 5 (0.99%) of 502 patients in the control group. There was no statistically significant difference between groups in terms of infection rates (p = 0.535). Staphylococcus aureus was found in 2 patients in the VP group. Two patients had S. aureus and 1 patient had Pseudomonas aeruginosa in the control group. There was no statistically significant difference between groups in terms of demographic parameters (p > 0.05). CONCLUSION: Intrawound VP administration doesn't change the infection rates in primary TKA. The VP administration for preventing PJI is not recommended in primary TKA. LEVEL OF EVIDENCE: III.
PURPOSE:Vancomycin powder (VP) has been used to prevent periprosthetic joint infection (PJI). However, studies investigating the efficacy of VP to prevent infection in primary total knee arthroplasty (TKA) are very rare. The purpose of this study was to investigate the efficacy of VP application to prevent PJI in TKA. METHODS: Between 2012 and 2016, 976 consecutive patients who underwent primary TKA were included in the present study. Patients were divided into two groups. There were 474 patients (48.6%) in the VP group and 502 patients in the control group (51.4%). Except for VP, all procedures were the same in both groups. In the VP group, 2 g of VP was poured into the joint just before the fascia was closed. Average follow-up was 53.2 months (24-84 months). RESULTS:Infection was found in 4 (0.84%) of 474 patients in the VP group and 5 (0.99%) of 502 patients in the control group. There was no statistically significant difference between groups in terms of infection rates (p = 0.535). Staphylococcus aureus was found in 2 patients in the VP group. Two patients had S. aureus and 1 patient had Pseudomonas aeruginosa in the control group. There was no statistically significant difference between groups in terms of demographic parameters (p > 0.05). CONCLUSION: Intrawound VP administration doesn't change the infection rates in primary TKA. The VP administration for preventing PJI is not recommended in primary TKA. LEVEL OF EVIDENCE: III.
Entities:
Keywords:
Local vancomycin powder; Periprosthetic joint infection; Primary total knee arthroplasty; Total knee replacement
Authors: Murray T Wong; Sarup S Sridharan; Erin M Davison; Richard Ng; Nicholas M Desy Journal: Clin Orthop Relat Res Date: 2021-08-01 Impact factor: 4.755
Authors: Wazzan S Aljuhani; Abdullah M Alanazi; Mohammad A Alghafees; Sondos H Sagor; Ali A Alhandi Journal: Saudi Med J Date: 2021-05 Impact factor: 1.422
Authors: Elysia A Masters; Benjamin F Ricciardi; Karen L de Mesy Bentley; T Fintan Moriarty; Edward M Schwarz; Gowrishankar Muthukrishnan Journal: Nat Rev Microbiol Date: 2022-02-15 Impact factor: 78.297
Authors: Kelly Moore; Rebecca Wilson-van Os; Devendra H Dusane; Jacob R Brooks; Craig Delury; Sean S Aiken; Phillip A Laycock; Anne C Sullivan; Jeffrey F Granger; Matthew V Dipane; Edward J McPherson; Paul Stoodley Journal: Antibiotics (Basel) Date: 2021-03-08